Last updated on June 2019

A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)


Brief description of study

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult patients aged 18 to 70 years, inclusive, for the prevention of PTH. Patients will provide written informed consent and during study visits they will use an electronic diary application daily, to report their headache status and other health information. Efficacy and immunogenicity status will be captured periodically and at study termination. The safety will be evaluated through adverse event report, concomitant medication inquiries, ECGs, clinical laboratory tests and physical examination. Additional evaluations will include pharmacokinetic, biomarker, and pharmacogenomics. All patients will continue the DB period in an open label period during 12 weeks with a monthly dose of 675 mg sc.

Clinical Study Identifier: NCT03347188

Find a site near you

Start Over

Teva Investigational Site 14061

Watertown, MA United States
0.39miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.